Results 91 to 100 of about 378 (110)

Castleman disease. [PDF]

Reumatologia
Qasim J, Ramasamy K.
europepmc   +1 more source

LRG1, a novel serum biomarker for iMCD disease activity. [PDF]

Biomark Res
Zhang MY, Yang ZH, Qiu YC, Gao YH, Li SY, Dang Y, Zhang L, Li J.   +7 more
europepmc   +1 more source

Real-world data of siltuximab for Chinese patients with iMCD: combination with BCD regimen as a potential approach for severe cases. [PDF]

Ann Hematol
Li SY, Gao YH, Dang Y, Chang L, Shen KN, Cai HC, Zhao DQ, Wei C, Feng J, Zhang L, Li J.   +10 more
europepmc   +1 more source

Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry. [PDF]

Blood Adv
Pierson SK, Brandstadter JD, Torigian DA, Bagg A, Lechowicz MJ, Alapat D, Casper C, Chadburn A, Chandrakasan S, Dispenzieri A, Fosså A, Hoffmann C, Ide M, Kurzrock R, Mukherjee S, Nasta S, Navarro JT, Noy A, Oksenhendler E, Bustamante MS, Shyamsundar S, Streetly M, Wong RSM, Zhang L, Lim MS, Srkalovic G, van Rhee F, Fajgenbaum DC.   +27 more
europepmc   +1 more source

Complications and Management of Idiopathic Multicentric Castleman Disease. [PDF]

HCA Healthc J Med
Feustel K, Keeling J, Makos O, Scherbak D.   +3 more
europepmc   +1 more source

Striped noncrystalline deposits within the expanded subendothelial space. [PDF]

Kidney Res Clin Pract
Ito H, Kannno A, Hirose T, Mori T.
europepmc   +1 more source

Siltuximab monotherapy improves progression free survival compared to rituximab-based therapies in patients with idiopathic multicentric Castleman disease; indirect comparison of studies using single-arm metanalysis method and the generalized linear mixed model. [PDF]

Ann Hematol
Karatisidis L, Mprotsis T, Intzes S, Zagoridis K, Vrachiolias G, Karatisidou V, Bezirgianidou Z, Liapis K, Kotsianidis I, Spanoudakis E.   +9 more
europepmc   +1 more source

[Sequential treatment with siltuximab and tocilizumab for childhood idiopathic multicentric Castleman disease: a case report]. [PDF]

Zhongguo Dang Dai Er Ke Za Zhi
Yi P, Zhang XX, Tang T, Wang Y, Wu XC, Li XF.   +5 more
europepmc   +1 more source

Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy. [PDF]

Hematology Am Soc Hematol Educ Program
Nijim S, Fajgenbaum DC.
europepmc   +1 more source